ArticleCancer medicine2024

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2- breast cancer.

Eduardo Terán et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.